Serosurvey and Cellular Immune Status of HTLV-1/2 and HIV Co-infections in Bauchi State, Nigeria

Authors

  • Adamu Babayo Department of Medical Microbiology and Parasitology, Faculty of Clinical Sciences, College of Health Sciences, Bayero University Kano, Kano State, Nigeria https://orcid.org/0000-0003-1039-486X
  • Akande Oyebanji Azeez Department of Medical Microbiology and Parasitology, Faculty of Clinical Sciences, College of Health Sciences, Bayero University Kano, Kano State, Nigeria https://orcid.org/0000-0003-2126-936X
  • Yusuf Mohammed Sabo Department of Medical Microbiology and Parasitology, Faculty of Clinical Sciences, College of Health Sciences, Bayero University Kano, Kano State, Nigeria
  • Idris Nasir Abdullahi Department of Medical Microbiology, University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria https://orcid.org/0000-0002-5511-1272
  • Amos Dangana Department of Laboratory Services, University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria

DOI:

https://doi.org/10.15584/ejcem.2019.4.1

Keywords:

HTLV, cellular Immunity, HIV co-infections, antiretroviral therapy

Abstract

Introduction. Human T-cell lymphotropic virus types 1 and 2 (HTLV-1 & 2) are frequent co-pathogens among immunosuppressed individuals, particularly HIV/AIDS infected persons. Dual infected persons usually present with false normal or high CD4+ T cells count as a result of the ability of HTLV to induce clonal proliferation of CD4+ T lymphocytes. There is paucity of information on this clinical entity in Nigeria.

Aim. This study aimed to determine the seroprevalence of HTLV-1/2 and associated cellular immune response among antiretroviral naïve and experienced HIV infected persons at Bauchi State, Nigeria.

Material and methods. One hundred and eighty two (182) HIV seropositive patients’ blood samples were analyzed for anti HTLV-1/2 IgM and IgG antibodies using ELISA while CD4+ T cells were counted using Flow cytometry technique. Socio-demographic data of the subjects and clinical history were obtained via questionnaire and medical records, respectively.

Results. The seroprevalence of anti-HTLV-1/2 was 14%. This comprised 76 (41.8%) males and 106 (58.2%) females. Six (3%) were seropositive for both ant-HTLV -1&2 IgM and IgG. Of the total positive for anti-HTLV-1/2, 20 (25%) ART-naïve and 6(5.9%) ART-experience subjects. Whole blood CD4+ T cell count was significantly high in HTLV-1/-2 IgG/IgM seropositive subjects compared to their HTLV-1/-2 negative counterpart.

Conclusion. All subjects (100%) who were HTLV-1/-2/HIV co-infected had normal to higher CD4+ T cell counts. It is suggested to be very careful in using only CD4+ counts to monitor HIV progression or as indicators for ART. 

Downloads

Download data is not yet available.

References

Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and Isolation of Type C Retrovirus Particles From Fresh And Cultured Lymphocytes of a Patient With Cutaneous T-Cell Lymphoma. PNAS U.S.A. 1980;77(12):7415-7419.

Pillotti E, Bianchi MV, Maria DA, et al. HTLV-1/-2 and HIV Co-Infections Retroviral Interference On Host Immune Status. Frontiers In Microbiology/Virology. 2013;372:1-13.

Switzer W, Heneine W, Owen S, et al. Human T-Cell Lymphotropic Viruses, D (ed), Manual of Clinical Microbiology. 2015. Eleventh Edition. ASM Press, Washington, DC:1458-1469.

Gessain A, Barin F, Vernant JC. Antibodies To Human Tlymphotropic Virus Type-I In-Patients With Tropical Spastic Paraparesis. Lancet. 1985:2:407-410.

Osame M, Usuku K, Isumo S, Ijichi N, Amitani H, Igata A. HTLV-I Associated-Myelopathy, A New Clinical Entity. Lancet. 1986;1:1031-1032.

Bartman MT, Kaidarova Z, Hirschkorn D. Long-Term Increases In Lymphocytes And Platelets In Human T-Lymphotropic Virus Type II Infection. Blood. 2008;112:3995-4002.

Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, Gallo RC. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science. 1982;218(4572):571-573.

Rosenblatt JD, Giorgi JV, Golde DW. Integrated Human T-Cell Leukemia Virus II Genome In CD8 + T Cells From A Patient With "Atypical" Hairy Cell Leukemia: Evidence For Distinct T And B Cell Lymphoproliferative Disorders. Blood. 1988;71(2):363-369.

Murphy EL. The Clinical Epidemiology Of Human T-Lymphotropic Virus Type II (HTLV-II). J Acquir Immune Defic Syndr. 1996;13:215-219.

Feigal E, Murphy E, Vranizan K. Human T cell lymphotropic virus types I and II in intravenous drug users in San Francisco: Risk factors associated with seropositivity. Journal of Infectious Diseases. 1991;164:36-42.

Fukushima Y, Takahashi H, Hall WW. Extraordinary high rate of HTLV type II seropositivity in intravenous drug abusers in South Vietnam. AIDS Response Human Retroviruses. 1995;11:637-645.

Hall WW, Takahashi H, Liu C. Multiple isolates and characteristics of human T-cell leukemia virus type II. Journal Virology. 1992;66:2456-2463.

Lee H, Swanson P, Shorty VS, Zack JA, Rosenblatt JD, Chen IS. High Rate Of HTLV-II Infection In Seropositive I.V. Drug Abusers In New Orleans. Science. 1989;244:471-475.

Tedder RS, Shanson DC, Jeffries DJ. Low Prevalence In The UK of HTLV-I and HTLV-II Infection In Subjects With AIDS, With Extended Lymphadenopathy, and at Risk of AIDS. Lancet. 1984;2:125-128.

Szczypinska EM. Human T-Cell Lymphotropic Viruses. Medscape.; Retrieved 8 January, 2018.

Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-1 infection and associated diseases. Oncogene. 2005;24:6058-6068.

Magri MC, Brigido LF, Morimoto HK, Caterino-de-Araujo, A. Human T cell lymphotropic virus type 2 a strains among HIV type1 Coinfected patients from Brazil have originated mostly from Brazilian Amerindians. AIDS Response Human Retroviruses. 2013;29:1010-1018.

Magri MC, Brigido LF, Rodrigues R, et al. Phylogenetic And Similarity Analysis Of HTLV- 1 Isolates From HIV-Coinfected Patients From The South And Southeast Regions Of Brazil. AIDS Response Human Retroviruses. 2012;28:110-114.

Martin ML, Adrade RG, Nadir BH. Human T-lymphotrophic viruses (HTLV). Blood transfusion in clinical practice. INTECH. 2012;10:176-188.

Nasir IA, Abdurrahman EA, Anthony UE, Muhammad SS, Jessy TM, Adamu B. Molecular Detection and Clinical Implications of HTLV-1 Infections among Antiretroviral Therapy-Naïve HIV-1-Infected Individuals in Abuja, Nigeria. Virology: Research and Treatment. 2015;6:17-23.

Durojaiye I, Akinbami A, Dosunmu A. Seroprevalence Of Human T-cell Lymphotropic Virus Antibodies Among Healthy Blood Donors at A Tertiary Centre In Lagos, Nigeria. Pan African Medical Journal. 2014;17:301.

Okoye AE, Ibegbulam OG, Onoh RC. Seroprevalence of human T-cell Lymphoma/leukemia virus type-1 (HTLV-1) antibodies among blood donors at Enugu, Nigeria. Journal Blood Medicine. 2015;6:31-36.

Brites C, Alencar R, Gusmao R, Pedroso C, Netto EM, Pedral-Sampaio D. Co-Infection with HTLV-1 Is Associated With A Shorter Survival Time For HIV-1-Infected Patients In Bahia, Brazil. AIDS. 2001;15:2053-2055.

Zane L, Sibon D, Mortreux F. Clonal expansion of HTLV-1 infected cells depends on the CD4 versus CD8 phenotype. Frontier of Biosciences. 2009;14:3935-3941.

Marriott SJ, Semmes OJ. Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene. 2005;24(39):5986-5995.

Hinuma Y. Retrovirus etiology of adult T-cell leukemia. Leukaemia Response. 1993;17:379-381.

Seaton RA, Wembri JP, Nwokolo N. Clinical associations with human T celllymphotropic virus type-I (HTLV-l) in Papua New Guinea. Med J Aust. 1996;165:403-406.

Nasir IA, Owolagba A, Ahmad AE, et al. Effects of first-line anti-retroviral therapy on blood coagulation parameters of HIV-infected patients attending a tertiary hospital at Abuja, Nigeria. Malays J Pathol. 2016;38(2):103-109.

Yuguda S, Manga MM, Fowotade A, Chukwuma OE, Aken’ova YA. Seroprevalence of Human T-Cell Lymphoma/Leukemia Virus Type-1 (HTLV-1) Antibodies among Blood Donors at Ibadan, Nigeria. J of Human Virol & Retrovi. 2015;5(5):2017.

Mohammed MM, Fowotade A, Yuguda S, et al. Serosurvey of human T cell lymphotropic virus I/II among blood donors in Gombe (Nigeria). Int J Blood Transfus Immunohematol. 2016;6:12-19.

Brites C, Alencar R, Gusmao R, Pedroso C, Netto EM, Pedral-Sampaio D. Co-Infection with HTLV-1 Is Associated With A Shorter Survival Time For HIV-1-Infected Patients In Bahia, Brazil. AIDS. 2001;15:2053-2055.

Anyanwu NCJ, Ella EE, Aminu M, Azam M, Ajmal M, Kazeem HM. Prevalence of human T-lymphotropic virus 1/2 in Nigeria's capital territory and meta-analysis of Nigerian studies. SAGE Open Med. 2019;7:2050312119843706.

Schechter M, Harrison LH, Halsey NA, Trade G, Santino M, Moulton LH. Coinfection With Human T-Cell Lymphotropic Virus Type I And HIV In Brazil. Impact on Markers of HIV Disease Progression. JAMA. 1994;271:353-357.

Fantry L, DeJonge E, Auwaerter PG, Lederman HM. Immunodeficiency And Elevated CD4 T-Lymphocyte Counts In Two Patients Co-infected With Human Immunodeficiency Virus And Human Lymphotropic Virus Type I. Clin Infec Dis. 1995;21:1466-1468.

Nadler JP, Bach MC, Godofsky E. Management of coinfection with human immunodeficiency virus and human T-cell lymphotropic virus type I. Clin Infec Dis. 1996;23:415.

Casseb J, Hong MA, Salomão S. Co-infection with human immunodeficiency virus and human T-cell lymphotropic virus type I: reciprocal activation with clinical and immunologic consequences. Clin Infec Dis. 1997;25:1259-1260.

Scapellato PG, Bottaro E, Rodriguez-Brieschke MT. CD4 cell count among HIV-infected patients with an AIDS-defining disease: higher count in patients co-infected than in those not coinfected with human T-cell lymphotropic virus type I. J Acqui Imm Defic. Syn. 2003;33:279-280.

van Veldhuisen PC, Walters M, Sawada T. Sero-incidence of human T-lymphotropic virus type I infection and characterization of sero-converters in Jamaican food handlers. Journal of Acqui Imm Defi Syn. 2003;33:387-392.

Gudo ES, Bhatt NB, Augusto O. Performance of absolute CD4+ count in predicting co-infection with human T-Lymphotropic virus type 1 in antiretroviral-naıve HIV-infected patients. International Journal of STD & AIDS. 2012;23:717-723.

Brites C, Alencar R, Gusmao R, Pedroso C, Netto EM, Pedral-Sampaio D. Co-Infection with HTLV-1 Is Associated With A Shorter Survival Time For HIV-1-Infected Patients In Bahia, Brazil. AIDS. 2001;15:2053-2055.

Ralph G, Mordechai A, Kuan-Teh J. Molecular mechanisms of cellular transformation by HTLV-1Tax. Oncogene. 2014;24:5976-5985.

Zane L, Sibon D, Mortreux F. Clonal expansion of HTLV-1 infected cells depends on the CD4+ versus CD8 phenotype. Frontier of Biosciences. 2009;14:3935-3941.

Downloads

Published

2019-12-30

How to Cite

Babayo, A., Azeez, A. O., Sabo, Y. M., Abdullahi, I. N., & Dangana, A. (2019). Serosurvey and Cellular Immune Status of HTLV-1/2 and HIV Co-infections in Bauchi State, Nigeria. European Journal of Clinical and Experimental Medicine, 17(4), 289–294. https://doi.org/10.15584/ejcem.2019.4.1

Issue

Vol. 17 No. 4 (2019)

Section

ORIGINAL PAPERS

License

Copyright (c) 2019 European Journal of Clinical and Experimental Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.

Most read articles by the same author(s)